As shown, patients who received biosimilar Peg-filgrastim were significantly older (p < 0.001), more frequently affected by myeloma and then treated with melphalan-based conditioning regimens (p = 0.004) and were infused with a significantly lower number of CD34 + cells (p < 0.001). This evidence concerns the gene CD34 and plasma cell myeloma.